Progesterone for the Prevention of Preterm Birth – an Update of Evidence-Based Indications

Ruben-J. Kuon; Pauline Voß; Werner Rath

doi:10.1055/a-0854-6472

Geburtshilfe und Frauenheilkunde, Table of Contents

CC BY-NC-ND 4.0 · Geburtshilfe Frauenheilkd 2019; 79(08): 844-853
DOI: 10.1055/a-0854-6472

GebFra Science

Review/Übersicht

Georg Thieme Verlag KG Stuttgart · New York

Progesterone for the Prevention of Preterm Birth – an Update of Evidence-Based Indications

Article in several languages: English | deutsch

Authors

Ruben-J. Kuon‡

¹Universitätsklinikum Heidelberg, Abteilung für Gynäkologische Endokrinologie und Fertilitätsstörungen, Frauenklinik, Heidelberg, Germany
Pauline Voß

¹Universitätsklinikum Heidelberg, Abteilung für Gynäkologische Endokrinologie und Fertilitätsstörungen, Frauenklinik, Heidelberg, Germany
Werner Rath‡

²Medizinische Fakultät Gynäkologie und Geburtshilfe, Universitätsklinikum Schleswig-Holstein, Campus Kiel, Kiel, Germany

Abstract

The prevention and treatment of preterm birth remains one of the biggest challenges in obstetrics. Worldwide, 11% of all children are born prematurely with far-reaching consequences for the children concerned, their families and the health system. Experimental studies suggest that progesterone inhibits uterine contractions, stabilises the cervix and has immunomodulatory effects. Recent years have seen the publication of numerous clinical trials using progestogens for the prevention of preterm birth. As a result of different inclusion criteria and the use of different progestogens and their methods of administration, it is difficult to draw comparisons between these studies. A critical evaluation of the available studies was therefore carried out on the basis of a search of the literature (1956 to 09/2018). Taking into account the most recent randomised, controlled studies, the following evidence-based recommendations emerge: In asymptomatic women with singleton pregnancies and a short cervical length on ultrasound of ≤ 25 mm before 24 weeks of gestation (WG), daily administration of vaginal progesterone (200 mg capsule or 90 mg gel) up until 36 + 6 WG leads to a significant reduction in the preterm birth rate and an improvement in neonatal outcome. The latest data also suggest positive effects of treatment with progesterone in cases of twin pregnancies with a short cervical length on ultrasound of ≤ 25 mm before 24 WG. The study data for the administration of progesterone in women with singleton pregnancies with a previous preterm birth have become much more heterogeneous, however. It is not possible to make a general recommendation for this indication at present, and decisions must therefore be made on a case-by-case basis. Even if progesterone use is considered to be safe in terms of possible long-term consequences, exposure should be avoided where it is not indicated. Careful patient selection is crucial for the success of treatment.

Key words

preterm birth - progesterone - 17α-hydroxyprogesterone caproate - cervical length

Full Text

References

References/Literatur
1 Blencowe H, Cousens S, Chou D. et al. Born too soon: the global epidemiology of 15 million preterm births. Reprod Health 2013; 10 (Suppl. 01) S2
2 IQTIG. Bundesauswertung zum Erfassungsjahr 2017 – Geburtshilfe Qualitätsindikatoren. Online: https://iqtig.org/downloads/auswertung/2017/16n1gebh/QSKH_16n1-GEBH_2017_BUAW_V02_2018-08-01.pdf last access: 31.03.2019
3 Vogel JP, Chawanpaiboon S, Moller AB. et al. The global epidemiology of preterm birth. Best Pract Res Clin Obstet Gynaecol 2018; 52: 3-12
4 Rotteveel J, van Weissenbruch MM, Twisk JWR. et al. Infant and childhood growth patterns, insulin sensitivity, and blood pressure in prematurely born young adults. Pediatrics 2008; 122: 313-321
5 Lindström K, Winbladh B, Haglund B. et al. Preterm infants as young adults: a Swedish national cohort study. Pediatrics 2007; 120: 70-77
6 Goldenberg RL, Culhane JF, Iams JD. et al. Epidemiology and causes of preterm birth. Lancet 2008; 371: 75-84
7 Rath W, Kehl S. Acute Tocolysis – a Critical Analysis of Evidence-Based Data. Geburtsh Frauenheilk 2018; 78: 1245-1255
8 Kyvernitakis I, Maul H, Bahlmann F. Controversies about the Secondary Prevention of Spontaneous Preterm Birth. Geburtsh Frauenheilk 2018; 78: 585-595
9 Ruddock NK, Shi S-Q, Jain S. et al. Progesterone, but not 17-alpha-hydroxyprogesterone caproate, inhibits human myometrial contractions. Am J Obstet Gynecol 2008; 199: 391.e1-391.e7
10 Garfield RE, Saade G, Buhimschi C. et al. Control and assessment of the uterus and cervix during pregnancy and labour. Hum Reprod Update 1998; 4: 673-695
11 Furcron AE, Romero R, Plazyo O. et al. Vaginal progesterone, but not 17α-hydroxyprogesterone caproate, has antiinflammatory effects at the murine maternal-fetal interface. Am J Obstet Gynecol 2015; 213: 846.e1-846.e19
12 Kuon RJ, Shi S-Q, Maul H. et al. Pharmacologic actions of progestins to inhibit cervical ripening and prevent delivery depend on their properties, the route of administration, and the vehicle. Am J Obstet Gynecol 2010; 202: 455.e1-455.9
13 Ananth CV, Getahun D, Peltier MR. et al. Recurrence of spontaneous versus medically indicated preterm birth. Am J Obstet Gynecol 2006; 195: 643-650
14 OʼBrien JM, Adair CD, Lewis DF. et al. Progesterone vaginal gel for the reduction of recurrent preterm birth: primary results from a randomized, double-blind, placebo-controlled trial. Ultrasound Obstet Gynecol 2007; 30: 687-696
15 Crowther CA, Ashwood P, McPhee AJ. et al. Vaginal progesterone pessaries for pregnant women with a previous preterm birth to prevent neonatal respiratory distress syndrome (the PROGRESS Study): A multicentre, randomised, placebo-controlled trial. PLoS Med 2017; 14: e1002390
16 Norman JE, Marlow N, Messow CM. et al. Vaginal progesterone prophylaxis for preterm birth (the OPPTIMUM study): a multicentre, randomised, double-blind trial. Lancet 2016; 387: 2106-2116
17 Ashoush S, El-Kady O, Al-Hawwary G. et al. The value of oral micronized progesterone in the prevention of recurrent spontaneous preterm birth: a randomized controlled trial. Acta Obstet Gynecol Scand 2017; 96: 1460-1466
18 Onsrud M, Paus E, Haug E. et al. Intramuscular Administration of Hydroxyprogesterone Caproate in patients with Endometrial Carcinoma: Pharmacokinetics and effects on adrenal function. Acta Obstet Gynecol Scand 1985; 64: 519-523
19 Romero R, Yeo L, Miranda J. et al. A blueprint for the prevention of preterm birth: vaginal progesterone in women with a short cervix. J Perinat Med 2013; 41: 27-44
20 Maher MA, Abdelaziz A, Ellaithy M. et al. Prevention of preterm birth: a randomized trial of vaginal compared with intramuscular progesterone. Acta Obstet Gynecol Scand 2013; 92: 215-222
21 Elimian A, Smith K, Williams M. et al. A randomized controlled trial of intramuscular versus vaginal progesterone for the prevention of recurrent preterm birth. Int J Gynaecol Obstet 2016; 134: 169-172
22 Bafghi AST, Bahrami E, Sekhavat L. Comparative Study of Vaginal versus Intramuscular Progesterone in the Prevention of Preterm Delivery: A Randomized Clinical Trial. Electron Physician 2015; 7: 1301-1309
23 Saccone G, Khalifeh A, Elimian A. et al. Vaginal progesterone vs intramuscular 17α-hydroxyprogesterone caproate for prevention of recurrent spontaneous preterm birth in singleton gestations: systematic review and meta-analysis of randomized controlled trials. Ultrasound Obstet Gynecol 2017; 49: 315-321
24 Oler E, Eke AC, Hesson A. Meta-analysis of randomized controlled trials comparing 17α-hydroxyprogesterone caproate and vaginal progesterone for the prevention of recurrent spontaneous preterm delivery. Int J Gynaecol Obstet 2017; 138: 12-16
25 Dodd JM, Jones L, Flenady V. et al. Prenatal administration of progesterone for preventing preterm birth in women considered to be at risk of preterm birth. Cochrane Database Syst Rev 2013; (07) CD004947
26 Dodd JM, Grivell RM, OBrien CM. et al. Prenatal administration of progestogens for preventing spontaneous preterm birth in women with a multiple pregnancy. Cochrane Database Syst Rev 2017; (10) CD012024
27 Serra V, Perales A, Meseguer J. et al. Increased doses of vaginal progesterone for the prevention of preterm birth in twin pregnancies: a randomised controlled double-blind multicentre trial. BJOG 2013; 120: 50-57
28 Rust OA, Atlas RO, Kimmel S. et al. Does the presence of a funnel increase the risk of adverse perinatal outcome in a patient with a short cervix?. Am J Obstet Gynecol 2005; 192: 1060-1066
29 Romero R, Conde-Agudelo A, da Fonseca E. et al. Vaginal progesterone for preventing preterm birth and adverse perinatal outcomes in singleton gestations with a short cervix: a meta-analysis of individual patient data. Am J Obstet Gynecol 2018; 218: 161-180
30 Romero R, Nicolaides KH, Conde-Agudelo A. et al. Vaginal progesterone decreases preterm birth ≤ 34 weeks of gestation in women with a singleton pregnancy and a short cervix: an updated meta-analysis including data from the OPPTIMUM study. Ultrasound Obstet Gynecol 2016; 48: 308-317
31 Fonseca EB, Celik E, Parra M. et al. Progesterone and the Risk of Preterm Birth among Women with a Short Cervix. N Engl J Med 2007; 357: 462-469
32 DeFranco EA, OʼBrien JM, Adair CD. et al. Vaginal progesterone is associated with a decrease in risk for early preterm birth and improved neonatal outcome in women with a short cervix: a secondary analysis from a randomized, double-blind, placebo-controlled trial. Ultrasound Obstet Gynecol 2007; 30: 697-705
33 Cetingoz E, Cam C, Sakallı M. et al. Progesterone effects on preterm birth in high-risk pregnancies: a randomized placebo-controlled trial. Arch Gynecol Obstet 2011; 283: 423-429
34 Hassan SS, Romero R, Vidyadhari D. et al. Vaginal progesterone reduces the rate of preterm birth in women with a sonographic short cervix: a multicenter, randomized, double-blind, placebo-controlled trial. Ultrasound Obstet Gynecol 2011; 38: 18-31
35 McNamara HC, Wood R, Chalmers J. et al. STOPPIT Baby Follow-up Study: the effect of prophylactic progesterone in twin pregnancy on childhood outcome. PLoS One 2015; 10: e0122341
36 Vedel C, Larsen H, Holmskov A. et al. Long-term effects of prenatal progesterone exposure: neurophysiological development and hospital admissions in twins up to 8 years of age. Ultrasound Obstet Gynecol 2016; 48: 382-389
37 Combs CA. Vaginal progesterone for asymptomatic cervical shortening and the case for universal screening of cervical length. Am J Obstet Gynecol 2012; 206: 101-103
38 Khalifeh A, Berghella V. Universal cervical length screening in singleton gestations without a previous preterm birth: ten reasons why it should be implemented. Am J Obstet Gynecol 2016; 214: 603.e1-603.e5
39 Campbell S. Universal cervical-length screening and vaginal progesterone prevents early preterm births, reduces neonatal morbidity and is cost saving: doing nothing is no longer an option. Ultrasound Obstet Gynecol 2011; 38: 1-9
40 Kuon RJ, Abele H, Berger R. et al. [Progesterone for Prevention of Preterm Birth–Evidence-based Indications]. Z Geburtshilfe Neonatol 2015; 219: 125-135
41 Conde-Agudelo A, Romero R. Vaginal progesterone to prevent preterm birth in pregnant women with a sonographic short cervix: clinical and public health implications. Am J Obstet Gynecol 2016; 214: 235-242
42 Pedretti MK, Kazemier BM, Dickinson JE. et al. Implementing universal cervical length screening in asymptomatic women with singleton pregnancies: challenges and opportunities. Aust N Z J Obstet Gynaecol 2017; 57: 221-227
43 Goodnight W. Clinical Application of Progesterone for the Prevention of Preterm Birth, 2016. Am J Perinatol 2016; 33: 253-257
44 Vintzileos AM, Visser GHA. Interventions for women with mid-trimester short cervix: which ones work?. Ultrasound Obstet Gynecol 2017; 49: 295-300
45 Newnham JP, Kemp MW, White SW. et al. Applying Precision Public Health to Prevent Preterm Birth. Front Public Health 2017; 5: 66
46 Fonseca EB, Celik E, Parra M. et al. Fetal Medicine Foundation Second Trimester Screening Group. Progesterone and the risk of preterm birth among women with a short cervix. N Engl J Med 2007; 357: 462-469
47 Rode L, Klein K, Nicolaides KH. et al. for the PREDICT Group. Prevention of preterm delivery in twin gestations (PREDICT): a multicenter, randomized, placebo-controlled trial on the effect of vaginal micronized progesterone. Ultrasound Obstet Gynecol 2011; 38: 272-280
48 El-Refaie W, Abdelhafez MS, Badawy A. Vaginal progesterone for prevention of preterm labor in asymptomatic twin pregnancies with sonographic short cervix: a randomized clinical trial of efficacy and safety. Arch Gynecol Obstet 2015; 293: 61-67
49 Brizot ML, Hernandez W, Liao AW. et al. Vaginal progesterone for the prevention of preterm birth in twin gestations: a randomized placebo-controlled double-blind study. Am J Obstet Gynecol 2015; 213: 82.e1-82.e9
50 Romero R, Conde-Agudelo A, El-Refaie W. et al. Vaginal progesterone decreases preterm birth and neonatal morbidity and mortality in women with a twin gestation and a short cervix: an updated meta-analysis of individual patient data. Ultrasound Obstet Gynecol 2017; 49: 303-314
51 Meis PJ, Klebanoff M, Thom E. et al. Prevention of recurrent preterm delivery by 17 alpha-hydroxyprogesterone caproate. N Engl J Med 2003; 348: 2379-2385
52 Northen AT, Norman GS, Anderson K. et al. Follow-up of children exposed in utero to 17 alpha-hydroxyprogesterone caproate compared with placebo. Obstet Gynecol 2007; 110: 865-872
53 Norwitz ER, Caughey AB. Progesterone supplementation and the prevention of preterm birth. Rev Obstet Gynecol 2011; 4: 60-72
54 Friedler S. Luteal support with micronized progesterone following in-vitro fertilization using a down-regulation protocol with gonadotrophin-releasing hormone agonist: a comparative study between vaginal and oral administration. Hum Reprod 1999; 14: 1944-1948
55 Norwitz ER, Caughey AB. Progesterone supplementation and the prevention of preterm birth. Rev Obstet Gynecol 2011; 4: 60-72
56 De Ziegler D, Bulletti C, De Monstier B. et al. The first uterine pass effect. Ann N Y Acad Sci 1997; 828: 291-299
57 Levy T. Pharmacokinetics of the progesterone-containing vaginal tablet and its use in assisted reproduction. Steroids 2000; 65: 645-649
58 OʼBrien JM, Lewis DF. Prevention of preterm birth with vaginal progesterone or 17-alpha-hydroxyprogesterone caproate: a critical examination of efficacy and safety. Am J Obstet Gynecol 2016; 214: 45-56
59 Ahn KH, Bae NY, Hong SC. et al. The safety of progestogen in the prevention of preterm birth: meta-analysis of neonatal mortality. J Perinat Med 2017; 45: 11-20
60 da Fonseca EB, Bittar RE, de Carvalho MH. et al. Prophylactic administration of progesterone by vaginal suppository to reduce the incidence of spontaneous preterm birth in women at increased risk: a randomized placebo-controlled double-blind study. Am J Obstet Gynecol 2003; 188: 419-424
61 Azargoon A, Ghorbani R, Aslebahar F. Vaginal progesterone on the prevention of preterm birth and neonatal complications in high risk women: A randomized placebo-controlled double-blind study. Int J Reprod Biomed (Yazd) 2016; 14: 309-316
62 Rai P, Rajaram S, Goel N. et al. Oral micronized progesterone for prevention of preterm birth. Int J Gynaecol Obstet 2009; 104: 40-43
63 Glover MM, McKenna DS, Downing CM. et al. A randomized trial of micronized progesterone for the prevention of recurrent preterm birth. Am J Perinatol 2011; 28: 377-381
64 Society for Maternal-Fetal Medicine Publications Committee, with assistance of Vincenzo Berghella. Progesterone and preterm birth prevention: translating clinical trials data into clinical practice. Am J Obstet Gynecol 2012; 206: 376-386
65 Society for Maternal-Fetal Medicine Publications Committee. The choice of progestogen for the prevention of preterm birth in women with singleton pregnancy and prior preterm birth. Am J Obstet Gynecol 2017; 216: B11-B13
66 Lim AC, Hegeman MA, Huis In ʼT Veld MA. et al. Cervical length measurement for the prediction of preterm birth in multiple pregnancies: a systematic review and bivariate meta-analysis. Ultrasound Obstet Gynecol 2011; 38: 10-17
67 Roman A, Da Silva Costa F, Araujo Júnior E. et al. Rescue Adjuvant Vaginal Progesterone May Improve Outcomes in Cervical Cerclage Failure. Geburtsh Frauenheilk 2018; 78: 785-790
68 Winer N, Bretelle F, Senat MV. et al. Groupe de Recherche en Obstétrique et Gynécologie. 17 alpha-hydroxyprogesterone caproate does not prolong pregnancy or reduce the rate of preterm birth in women at high risk for preterm delivery and a short cervix: a randomized controlled trial. Am J Obstet Gynecol 2015; 212: 485.e1-485.e10